These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 16937430)

  • 1. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological therapies for inflammatory bowel disease: research drives clinics.
    Danese S; Semeraro S; Armuzzi A; Papa A; Gasbarrini A
    Mini Rev Med Chem; 2006 Jul; 6(7):771-84. PubMed ID: 16842127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].
    Flamant M; Bourreille A
    Rev Med Interne; 2007 Dec; 28(12):852-61. PubMed ID: 17628232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
    Van Assche G; Vermeire S; Rutgeerts P
    Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic targeting in the treatment of inflammatory bowel diseases.
    Bosani M; Ardizzone S; Porro GB
    Biologics; 2009; 3():77-97. PubMed ID: 19707398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TNF-alpha inhibitors in inflammatory bowel disease].
    Casellas i Jordà F
    Med Clin (Barc); 2004 Nov; 123(16):627-34. PubMed ID: 15546523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical perspectives--biologics in IBD: What's all the fuss?
    Steinhart H
    Can J Gastroenterol; 2001 Dec; 15(12):799-804. PubMed ID: 11773946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.
    Ghosh N; Chaki R; Mandal SC
    Int Rev Immunol; 2012 Oct; 31(5):410-27. PubMed ID: 23083349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition.
    Rutgeerts P; Van Deventer S; Schreiber S
    Aliment Pharmacol Ther; 2003 Jun; 17(12):1435-50. PubMed ID: 12823145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in inflammatory bowel disease.
    Ahluwalia JP
    Med Clin North Am; 2012 May; 96(3):525-44, x. PubMed ID: 22703854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
    Ogata H; Hibi T
    Curr Pharm Des; 2003; 9(14):1107-13. PubMed ID: 12769750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.
    Holleran G; Lopetuso L; Petito V; Graziani C; Ianiro G; McNamara D; Gasbarrini A; Scaldaferri F
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in biological therapy for inflammatory bowel disease.
    Kurtovic J; Segal I
    Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiadhesion molecule therapy in inflammatory bowel disease.
    van Assche G; Rutgeerts P
    Inflamm Bowel Dis; 2002 Jul; 8(4):291-300. PubMed ID: 12131614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.